A detailed history of Black Rock Inc. transactions in Repare Therapeutics Inc. stock. As of the latest transaction made, Black Rock Inc. holds 141,803 shares of RPTX stock, worth $462,277. This represents 0.0% of its overall portfolio holdings.

Number of Shares
141,803
Previous 61,265 131.46%
Holding current value
$462,277
Previous $288,000 62.15%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$3.02 - $4.7 $243,224 - $378,528
80,538 Added 131.46%
141,803 $467,000
Q1 2024

May 10, 2024

SELL
$4.53 - $8.41 $6,505 - $12,076
-1,436 Reduced 2.29%
61,265 $288,000
Q4 2023

Feb 13, 2024

SELL
$3.22 - $11.79 $866,659 - $3.17 Million
-269,149 Reduced 81.11%
62,701 $457,000
Q3 2023

Nov 13, 2023

BUY
$8.16 - $13.01 $179,234 - $285,764
21,965 Added 7.09%
331,850 $4.01 Million
Q2 2023

Aug 11, 2023

SELL
$8.63 - $12.53 $1.11 Million - $1.61 Million
-128,632 Reduced 29.33%
309,885 $3.28 Million
Q1 2023

May 12, 2023

SELL
$9.32 - $15.06 $182,662 - $295,160
-19,599 Reduced 4.28%
438,517 $4.32 Million
Q4 2022

Feb 13, 2023

BUY
$12.5 - $18.13 $595,500 - $863,713
47,640 Added 11.61%
458,116 $6.74 Million
Q3 2022

Nov 14, 2022

SELL
$11.57 - $15.59 $29,977 - $40,393
-2,591 Reduced 0.63%
410,476 $4.98 Million
Q2 2022

Aug 12, 2022

SELL
$8.45 - $14.84 $458,361 - $804,980
-54,244 Reduced 11.61%
413,067 $5.78 Million
Q1 2022

May 12, 2022

BUY
$11.38 - $21.88 $98,778 - $189,918
8,680 Added 1.89%
467,311 $6.66 Million
Q4 2021

Feb 10, 2022

BUY
$19.66 - $28.11 $660,458 - $944,327
33,594 Added 7.9%
458,631 $9.67 Million
Q3 2021

Nov 09, 2021

BUY
$25.71 - $35.24 $323,663 - $443,636
12,589 Added 3.05%
425,037 $11.2 Million
Q2 2021

Aug 11, 2021

BUY
$30.1 - $34.85 $12.4 Million - $14.4 Million
412,448 New
412,448 $12.9 Million

Others Institutions Holding RPTX

About Repare Therapeutics Inc.


  • Ticker RPTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,937,800
  • Market Cap $137M
  • Description
  • Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that foc...
More about RPTX
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.